Pfizer Inc. (PFE:NYE) Analysts rate with a Buy, $61 target

STA Research
by: STA Research

Based on the Pfizer Inc. stock forecasts from 16 analysts, the average analyst target price for Pfizer Inc. is USD 61.23 over the next 12 months. Pfizer Inc.’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of Pfizer Inc. is Bullish, which is based on 12 positive signals and 4 negative signals. At the last closing, Pfizer Inc.’s stock price was USD 53.91. Pfizer Inc.’s stock price has changed by +1.44% over the past week, +4.84% over the past month and +39.19% over the last year.

Berenberg Capital Markets on Friday, maintained the Hold rating and $50 target on the pharma stock.

Pfizer Inc. is a global biopharmaceutical company that develops, manufactures, promotes, distributes, and sells biopharmaceutical drugs. Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Myovant Sciences Ltd., Akcea Therapeutics, Inc., Merck KGaA, Valneva SE, BioNTech SE, and Arvinas, Inc. have all signed collaboration agreements with the company. Pfizer Inc. is based in New York, New York, and was founded in 1849.

What we like:

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on a total return basis, for investors seeking high-income yields.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price-to-book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on a cash flow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on assets

The company management has delivered a better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on a free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

Compared to its sector, this stock has shown top quartile revenue growth in the previous 5 years.

 

Berenberg Capital Markets targets Pfizer Inc. stock at a $50 target

 

What we don’t like:

High volatility

The total returns for this company are volatile and above the median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.

 

 

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.